{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-037353","form_type":"8-K","ticker":"ZLAB","cik":"0001704292","company_name":"Zai Lab Ltd","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.110293+00:00","generated_at":"2026-06-08T16:14:48.493913+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zai Lab Q3 revenue $69.2M (+22% YoY); launches VYVGART in China, net loss narrows","bullets":["Product revenue $69.2M, up 22% YoY; VYVGART contributed $4.9M since September launch.","Net loss $69.2M vs $161.2M in Q3 2022; R&D expenses fell to $58.8M from $99.5M.","Cash $822.2M at Sept 30, down from $876.4M at June 30, 2023.","Terminated ZL-1211 (Claudin18.2) development; appointed Dr. Robert Brown as CMO, Oncology.","Expects at least seven product launches in 2-3 years; multiple NDAs under review (repotrectinib, odronextamab)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-037353","json":"https://secwatch.observer/filing/0001628280-23-037353.json","markdown":"https://secwatch.observer/filing/0001628280-23-037353.md","text":"https://secwatch.observer/filing/0001628280-23-037353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704292/000162828023037353/0001628280-23-037353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704292/000162828023037353/zlab-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T16:14:48.493913+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"62e49de2a3c0ff24840beeb66f5471c733d343de","claim":"Zai Lab Ltd reported third quarter 2023 results: revenue $69.2 million, net income $69.2 million, EPS $0.07.","evidence_excerpt":"Third Quarter 2023 Financial Results • Product revenues were $69.2 million for the third quarter of 2023, compared to $57.0 million for the same period in 2022, representing 22% y-o-y growth and 27% y-o-y growth at CER. This increase was primarily driven by increased sales volumes, the launch of VYVGART, and decreased negative effects from the COVID-19 pandemic . Our revenue growth was slowed by the effects on hospital and physician practices from the recent industry-wide anti-corruption enforcement efforts in China. Product revenues in the third quarter of 2023, compared to the same period in 2022, included: – $41.6 million for ZEJULA, which increased from $39.2 million, as ZEJULA, which is in its third year on the NRDL, continued to be the leading PARP inhibitor in hospital sales for ovarian cancer in China; – $11.6 million for Optune, which increased from $10.7 million, supported by increased patient access to this product in the private-pay market; – $5.7 million for QINLOCK, which","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704292/000162828023037353/0001628280-23-037353-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Revenue","value":"$69.2 million"},{"label":"Net income","value":"$69.2 million"},{"label":"EPS","value":"$0.07"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}